Aliskiren (Speedel) [0.03%]
阿利克仑(Speedel)
Kristina Allikmets
Kristina Allikmets
Speedel Pharma is developing aliskiren (formerly CGP-60536), a renin inhibitor under license from Novartis, for the potential treatment of several cardiovascular disorders. By October 2001, a phase IIb study in hypertension had been complet...
Hongwei Zhang
Hongwei Zhang
The Medicines Company (under license from AstraZeneca) is developing clevidipine, a short-acting dihydropyridine calcium antagonist, for the potential treatment of peri-operative hypertension. By 1997, the compound was undergoing phase II c...
The role of aldosterone receptor blockade in the management of cardiovascular disease [0.03%]
醛固酮受体拮抗剂在心血管疾病治疗中的作用
Danny Liew,Henry Krum
Danny Liew
The recent revival of interest in aldosterone receptor antagonists for the treatment of cardiovascular disease has been underpinned by fresh insights into the pathophysiological role of aldosterone in cardiovascular disease, especially with...
Inolimomab (OPi) [0.03%]
奥普利单抗(Inolimomab)
Michael Winkler
Michael Winkler
OPi (formerly Orphan Pharma International) is developing inolimomab, an anti-interleukin-2 receptor (CD25) monoclonal antibody for the potential treatment of acute graft versus host disease. As of April 2001, inolimomab was undergoing phase...
1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation [0.03%]
1,25-二羟基维生素D3类似物在移植中的潜在治疗作用
Luciano Adorini
Luciano Adorini
While immunosuppressive drugs now permit good control of acute allograft rejection, chronic rejection remains an important medical problem, and the induction of stable transplantation tolerance has not yet been achieved in patients. 1,25-Di...
Overview: transplantation tolerance--challenges and opportunities for drug development [0.03%]
概要：移植耐受——药物开发的挑战与机遇
Francis J Dumont
Francis J Dumont
Clive Yeates
Clive Yeates
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis. ...
DNA binding compounds targeting fungal pathogens: an emerging concept in the discovery of novel antifungal agents [0.03%]
靶向真菌病原体的DNA结合化合物：发现新型抗真菌剂的新概念
Lillian Lou,Mark Velligan,Christopher Roberts et al.
Lillian Lou et al.
With the urgent need for novel agents to combat emerging fungal resistance to existing drugs, activity in the exploration of small molecule DNA binders has increased. Recently, selected cationic heterocyclic compounds belonging to a broad c...
The role of caspofungin and the echinocandins in the antifungal armamentarium [0.03%]
棘白球菌素类在抗真菌药物中的地位和作用
Vicki A Morrison
Vicki A Morrison
The echinocandins are a recently-developed class of antifungal agents that interfere with fungal cell wall synthesis through the inhibition of glucan synthesis. Although several intravenous preparations are in various stages of development,...
CCI-779 Wyeth [0.03%]
威治公司CCI-779
Laurie Elit
Laurie Elit
Wyeth Research (formerly Wyeth-Ayerst Research) is developing the sirolimus (rapamycin) analog CCI-779 as a potential treatment for various cancers [320924]. By November 2001, phase III trials had been initiated [428972], [429576]. In Octob...